Original Article

You have full text access to this OnlineOpen article

A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug–refractory ankylosing spondylitis

  1. Walter P. Maksymowych1,*,
  2. Gian S. Jhangri1,
  3. Avril A. Fitzgerald1,
  4. Sharon LeClercq1,
  5. Peter Chiu2,
  6. Alex Yan2,
  7. Kenneth J. Skeith2,
  8. Stephen L. Aaron1,
  9. Joanne Homik1,
  10. Paul Davis1,
  11. Dale Sholter2,
  12. Anthony S. Russell1

Article first published online: 7 MAR 2002

DOI: 10.1002/art.10139

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 46, Issue 3, pages 766–773, March 2002

Additional Information

How to Cite

Maksymowych, W. P., Jhangri, G. S., Fitzgerald, A. A., LeClercq, S., Chiu, P., Yan, A., Skeith, K. J., Aaron, S. L., Homik, J., Davis, P., Sholter, D. and Russell, A. S. (2002), A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug–refractory ankylosing spondylitis. Arthritis & Rheumatism, 46: 766–773. doi: 10.1002/art.10139

Author Information

  1. 1

    University of Alberta, Edmonton, Alberta, Canada

  2. 2

    Edmonton, Alberta, Canada

*562 Heritage Medical Research Building, University of Alberta, Edmonton, Alberta T6G 2S2, Canada

Publication History

  1. Issue published online: 7 MAR 2002
  2. Article first published online: 7 MAR 2002
  3. Manuscript Accepted: 24 OCT 2001
  4. Manuscript Received: 27 JUL 2001

Funded by

  • Arthritis Society of Canada
  • Canadian Institutes of Health. Grant Number: MCT-37411

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (99K)

REFERENCES

  • 1
    Dougados M, Behier JM, Jolchine I, Calin A, van der Heijde D, Olivieri I, et al. Efficacy of celecoxib, a cyclooxygenase 2–specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001; 44: 180–5.
    Direct Link:
  • 2
    Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal antiinflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104: 1832–47.
  • 3
    Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38: 618–27.
    Direct Link:
  • 4
    Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. Arthritis Rheum 1996; 39: 2004–12.
    Direct Link:
  • 5
    Ahlstrom H, Feltelius N, Nyman R, Hallgren R. Magnetic resonance imaging of sacroiliac joint inflammation. Arthritis Rheum 1990; 33: 1763–9.
    Direct Link:
  • 6
    McGonagle D, Gibbon W, O'Connor P, Green M, Pease C, Emery P. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum 1998; 41: 694–700.
    Direct Link:
  • 7
    Pasion EG, Goodfellow JW, Pasion EG, Goodfellow JW. Pre-ankylosing spondylitis: histopathological report. Ann Rheum Dis 1975; 34: 92–7.
  • 8
    Schichikawa K, Tsyimoto M, Nishioka J, Nishibayashi Y, Matsumoto K. Histopathology of early sacroiliitis and enthesitis in ankylosing spondylitis. In: ZiffM, CohenSB, editors. Advances in inflammation research: the spondyloarthropathies. Vol. 9. New York: Raven Press; 1985. p. 15–24.
  • 9
    Francois RJ, Gardner DL, Degrave EJ, Bywaters EGL. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis Rheum 2000; 43: 2011–24.
    Direct Link:
  • 10
    Van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999; 264: 108–11.
  • 11
    Luckman SP, Hughes DE, Coxon FP, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581–9.
    Direct Link:
  • 12
    Cecchini MG, Fleisch H. Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage. J Bone Miner Res 1990; 5: 1019–27.
    Direct Link:
  • 13
    Stevenson PH, Stevenson JR. Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages. Calcif Tissue Int 1986; 38: 227–33.
  • 14
    Sansoni P, Passeri G, Fagnoni F, Mohagheghpour N, Snelli G, Brianti V, et al. Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res 1995; 10: 1719–25.
    Direct Link:
  • 15
    Francis MD, Hovancik K, Boyce RW. NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tissue React 1989; 11: 239–52.
  • 16
    Barbier A, Breliere JC, Remandet B, Roncucci R. Studies on the chronic phase of adjuvant arthritis: effect of SR 41319, a new diphosphonate. Ann Rheum Dis 1986; 45: 67–74.
  • 17
    Maksymowych WP, Jhangri GS, LeClercq S, Skeith K, Yan A, Russell AS. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 1998; 25: 714–7.
  • 18
    Maksymowych WP, Lambert R, Jhangri GS, LeClercq S, Chiu P, Wong B, et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 2001; 28: 144–55.
  • 19
    Schweitzer DH, Oostendorp-Van de Ruit M, Van der Pluijm G, Lowik CW, Papapoulos SE. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 1995; 10: 956–62.
    Direct Link:
  • 20
    Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987; 41: 326–31.
  • 21
    Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361–8.
  • 22
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286–91.
  • 23
    Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281–5.
  • 24
    Jones SD, Steiner A, Garrett SL, Calin A. The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 1996; 35: 66–71.
  • 25
    Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994; 21: 1694–8.
  • 26
    Fenton AJ, Gutteridge DH, Kent GN, Price RI, Retallack RW, Bhagat CI, et al. Intravenous aminobisphosphonate in Paget's disease: clinical, biochemical, histomorphometric and radiological responses. Clin Endocrinol (Oxford) 1991; 34: 197–204.
    Direct Link:
  • 27
    Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999; 9 Suppl 2: S66–80.
  • 28
    Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) 1999; 38: 878– 82.
  • 29
    Amor B, Dougados M, Khan MA. Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am 1995; 21: 117–28.
  • 30
    Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000; 59: 428–33.
  • 31
    Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 1346–52.
    Direct Link:
  • 32
    Sato M, Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 1990; 5: 31–40.
    Direct Link:
  • 33
    Ralston SH, Hacking L, Willocks L, Bruce F, Pitkeathly DA. Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis 1989; 48: 396–9.
  • 34
    Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 1999; 26: 966–70.
  • 35
    Russell RG, Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 1999; 14: 53–65.
  • 36
    Van Offel JF, Schuerwegh AJ, Bridts CH, Bracke PG, Stevens WJ, De Clerck LS. Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate. Clin Exp Rheumatol 2001; 19: 13–20.
  • 37
    Pennanen N, Lapinjoki S, Urtti A, Monkkonen J. Effect of liposomal and free bisphosphonates on the IL-1β, IL-6 and TNFα secretion from RAW 264 cells in vitro. Pharm Res 1995; 12: 916–22.
  • 38
    Vasikaran SD, Khan S, McCloskey EV, Kanis JA. Sustained response to intravenous alendronate in postmenopausal osteoporosis. Bone 1995; 17: 517–20.
  • 39
    Pietschmann P, Stohlawetz P, Brosch S, Steiner G, Smolen JS, Peterlik M. The effect of alendronate on cytokine production, adhesion molecule expression, and transendothelial migration of human peripheral blood mononuclear cells. Calcif Tissue Int 1998; 63: 325–30.
  • 40
    Cantatore FP, Acquista CA, Pipitone V. Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol 1999; 26: 2318–23.
  • 41
    Felson DT, Chaisson CE, Hill CL, Totterman SM, Gale ME, Skinner KM, et al. The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med 2001; 134: 541–9.
  • 42
    McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement. Ann Rheum Dis 1999; 58: 156–63.
  • 43
    Toussirot E, Wendling D. Bone mass in ankylosing spondylitis. Clin Exp Rheumatol 2000; 18 Suppl 21: S16–20.
  • 44
    Laloux L, Voisin MC, Allain J, Martin N, Kerboull L, Chevalier X, et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 2001; 60: 316–21.
  • 45
    Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000; 88: 1082–90.
    Direct Link:
View Full Article (HTML) Get PDF (99K)